Kyverna Therapeutics, Inc. Common Stock Cash Flow-to-Debt Ratio
Kyverna Therapeutics, Inc. Common Stock cash flow-to-debt ratio. Kyverna Therapeutics, Inc. Common Stock (KYTX) has a Cash Flow-to-Debt Ratio of -0.68x as of March 2026, meaning its operating cash flow of $-41.60 Million could theoretically repay -1% of its total liabilities ($61.44 Million) in one year. See Kyverna Therapeutics, Inc. Common Stock leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Kyverna Therapeutics, Inc. Common Stock (2021–2025)
Cash flow-to-debt ratio of Kyverna Therapeutics, Inc. Common Stock from 2021 to 2025. Historical debt coverage capacity for Kyverna Therapeutics, Inc. Common Stock across 5 annual periods. Also explore Kyverna Therapeutics, Inc. Common Stock net asset momentum to track the company's year-over-year net asset growth rate.
Kyverna Therapeutics, Inc. Common Stock Cash Flow-to-Debt Ratio by Year (2021–2025)
Kyverna Therapeutics, Inc. Common Stock cash flow-to-debt ratio by year from 2021 to 2025. Year-by-year debt coverage analysis for Kyverna Therapeutics, Inc. Common Stock. For the full cash flow conversion analysis, see KYTX cash flow metrics.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.50x | $-153.71 Million | $61.55 Million | ▲ +16.8% |
| 2024 | -3.00x | $-114.25 Million | $38.06 Million | ▼ -49.0% |
| 2023 | -2.01x | $-52.41 Million | $26.02 Million | ▼ -12.9% |
| 2022 | -1.78x | $-36.11 Million | $20.25 Million | ▼ -960.6% |
| 2021 | -0.17x | $-22.16 Million | $131.74 Million | — |